tiprankstipranks
Trending News
More News >

Biotron Advances Hepatitis B Drug Development with Successful Safety Study

Story Highlights
  • Biotron has completed the first safety stage of its HBV drug study in mice.
  • The study’s progress marks a significant step in Biotron’s HBV program and commercialization efforts.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Biotron Advances Hepatitis B Drug Development with Successful Safety Study

Don’t Miss TipRanks’ Half-Year Sale

Biotron ( (AU:BIT) ) has issued an update.

Biotron Limited has completed the first stage of an animal study for its lead drug targeting Hepatitis B Virus (HBV), confirming the drug’s safety in mice. The study, conducted at the SCRIPPS Research Institute, aims to assess the antiviral activity of the drug in two mouse models, with the next phase focusing on its efficacy in treating HBV infection. This development is a significant step forward in Biotron’s HBV program, which seeks to address the global health challenge posed by chronic HBV infections. Concurrently, Biotron is advancing its commercialisation efforts, engaging with potential partners at industry events to further its programs, including those focused on HIV-1.

More about Biotron

Biotron Limited is a company focused on the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical needs. The company has BIT225 in clinical development for HIV-1 and COVID-19, and additional promising preclinical programs including Hepatitis B Virus (HBV). Biotron also works on designing drugs targeting viroporins, which are crucial in the virus life cycle of various viruses such as Coronavirus, Dengue, Ebola, and others.

Technical Sentiment Signal: Sell

Current Market Cap: A$2.65M

For an in-depth examination of BIT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1